Last reviewed · How we verify

AFQ056 with L-dopa — Competitive Intelligence Brief

AFQ056 with L-dopa (AFQ056 with L-dopa) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mGluR5 negative allosteric modulator. Area: Neurology.

phase 2 mGluR5 negative allosteric modulator mGluR5 (metabotropic glutamate receptor 5) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AFQ056 with L-dopa (AFQ056 with L-dopa) — Novartis. AFQ056 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator that reduces excessive glutamatergic signaling, combined with L-dopa to enhance dopaminergic activity in Parkinson's disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AFQ056 with L-dopa TARGET AFQ056 with L-dopa Novartis phase 2 mGluR5 negative allosteric modulator mGluR5 (metabotropic glutamate receptor 5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mGluR5 negative allosteric modulator class)

  1. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AFQ056 with L-dopa — Competitive Intelligence Brief. https://druglandscape.com/ci/afq056-with-l-dopa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: